OU School of Community Medicine

Emulate Earns Frost & Sullivan's 2023 Technology Innovation Leadership Award

Retrieved on: 
Thursday, October 12, 2023
Proximal tubule, Food and Drug Administration Modernization Act of 1997, Microfluidics, Toxicity, OU School of Community Medicine, Hepatotoxicity, Emulate, FDA, Physiology, College of Engineering (KNUST), Frost, Toxicology, Organ, SAN, Software, Patient, Medical imaging, Nature

SAN ANTONIO , Oct. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the North American Organ-on-a-Chip industry and, based on its findings, recognizes Emulate with the 2023 Technology Innovation Leadership Award for their successful development of Organ-on-a-Chip technology, which replicates the physiological processes and intricate intracellular networks of specific organs. The company is at the forefront of developing human-relevant Organ-Chip models, helping its customers to reduce and refine their dependence on animal models for preclinical studies.

Key Points: 
  • SAN ANTONIO , Oct. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the North American Organ-on-a-Chip industry and, based on its findings, recognizes Emulate with the 2023 Technology Innovation Leadership Award for their successful development of Organ-on-a-Chip technology, which replicates the physiological processes and intricate intracellular networks of specific organs.
  • Emulate Organ-Chip models are used by academia and the pharmaceutical industry across a wide variety of areas, including toxicology, immunology, gene therapy, and cancer research.
  • Within academia, Emulate Organ-Chips enable researchers to develop new models with closer-to-human gene expression to better understand human physiology and disease mechanisms.
  • For its strong overall performance, Emulate earns Frost & Sullivan's 2023 Technology Innovation Leadership Award in the North American Organ-on-a-Chip platform industry.

Emulate Earns Frost & Sullivan's 2023 Technology Innovation Leadership Award

Retrieved on: 
Thursday, October 12, 2023
Proximal tubule, Food and Drug Administration Modernization Act of 1997, Microfluidics, Toxicity, OU School of Community Medicine, Hepatotoxicity, Emulate, FDA, Physiology, College of Engineering (KNUST), Frost, Toxicology, Organ, SAN, Software, Patient, Medical imaging, Nature

SAN ANTONIO, Oct. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the North American Organ-on-a-Chip industry and, based on its findings, recognizes Emulate with the 2023 Technology Innovation Leadership Award for their successful development of Organ-on-a-Chip technology, which replicates the physiological processes and intricate intracellular networks of specific organs. The company is at the forefront of developing human-relevant Organ-Chip models, helping its customers to reduce and refine their dependence on animal models for preclinical studies.

Key Points: 
  • SAN ANTONIO, Oct. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the North American Organ-on-a-Chip industry and, based on its findings, recognizes Emulate with the 2023 Technology Innovation Leadership Award for their successful development of Organ-on-a-Chip technology, which replicates the physiological processes and intricate intracellular networks of specific organs.
  • Emulate Organ-Chip models are used by academia and the pharmaceutical industry across a wide variety of areas, including toxicology, immunology, gene therapy, and cancer research.
  • Within academia, Emulate Organ-Chips enable researchers to develop new models with closer-to-human gene expression to better understand human physiology and disease mechanisms.
  • For its strong overall performance, Emulate earns Frost & Sullivan's 2023 Technology Innovation Leadership Award in the North American Organ-on-a-Chip platform industry.

Juno Medical Opens New Health Care Office in the Heart of Tulsa's Greenwood District

Retrieved on: 
Tuesday, July 25, 2023
Juno, Food, University, Public health, Health, Pediatrics, OU School of Community Medicine, Health equity, Biting, University of Oklahoma, Patient, School, Archery, Environment, Family, Nightclub, Nursing

TULSA, Okla., July 25, 2023 /PRNewswire/ -- Juno Medical recently opened a new health care office in Tulsa's Greenwood District. Juno Medical — Tulsa now occupies 3,800 square feet on the ground floor of 21 North Greenwood, a four story development located near Archer and Greenwood. The company will host a grand opening celebration on July 25th and the public is invited. Kicking off with an official ribbon-cutting and opening remarks, guests can enjoy food and entertainment, tour the modern clinic, meet the providers, and learn about Juno's services.

Key Points: 
  • The company is reimagining healthcare for Tulsa families under the clinical leadership of Dr. Jabraan Pasha
    TULSA, Okla., July 25, 2023 /PRNewswire/ -- Juno Medical recently opened a new health care office in Tulsa's Greenwood District.
  • Juno Medical — Tulsa now occupies 3,800 square feet on the ground floor of 21 North Greenwood, a four story development located near Archer and Greenwood.
  • With a specific focus on addressing health disparities and engaging with underserved populations, Juno first opened in Harlem in 2020.
  • Located in the growing Greenwood District, Juno provides primary care, pediatrics, women's health, same-day care and more.

Covid Study of Unvaccinated Sample Puts Cutting-Edge Research on The Map

Retrieved on: 
Thursday, October 27, 2022
Infection, Sneeze, Institutional review board, COVID-19, FDA, Institute, OU School of Community Medicine, Oak Crest, Student, Education, NSF, Research, Severe acute respiratory syndrome coronavirus 2, Multimedia, HIV, STEM, Host, Environmental science, Pharmaceutical industry, Vaccine, Online shopping

MONROVIA, Calif., Oct. 27, 2022 /PRNewswire/ -- Waging the fight against Covid-19 from the front lines, Oak Crest Institute of Science has released groundbreaking findings with major medical and public health implications.

Key Points: 
  • Link to full abstract in Communications Medicine: https://www.nature.com/articles/s43856-022-00195-4
    Oak Crest is a non-profit research institute in Southern California that developed an FDA-approved reaction test to detect the virus on nasal swabs.
  • That led to selecting Oak Crest as an Institutional Review Board-approved clinical study site.
  • https://www.oak-crest.org/faculty-and-staff/
    Nine study participants who developed COVID-19 between November 2020 and March 2021 were monitored for three months.
  • Since its founding in 1998, Oak Crest has participated in educational programs, taking in groups to experience mentored research and near-peer mentoring.

Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®

Retrieved on: 
Monday, August 29, 2022
Nature, Lung cancer, Neoplasm, ENTPD1, Patient, Treatment, University, Technology, RNA, Cancer, Survival, Research, Gene, OS, RFS, Protein, Cell membrane, Solution, High, Adenosine, Randomized controlled trial, University of Alabama, HR, Society, Overalls, GM, Hope, GameChanger, VITAL, Colorectal cancer, OU School of Community Medicine, Skin, Maintenance, Diagnosis, CD39, DNA, HRP, Obstetrics, CSO, GLOBE, Epitope, Immune system, Immunotherapy, Biomarker, The Lancet, Clinical trial, Ovarian cancer, Gynaecology, Melanoma, American Society of Clinical Oncology, BRCA, Phase 1, Pharmaceutical industry, Medical imaging, Vaccine, DALLAS

High ENTPD1 was associated with improved RFS and OS following Vigil maintenance treatment in frontline ovarian cancer patients.

Key Points: 
  • High ENTPD1 was associated with improved RFS and OS following Vigil maintenance treatment in frontline ovarian cancer patients.
  • ENTPD1 has been identified as playing a role in numerous other solid tumor indications, including melanoma, lung cancer and colorectal cancer.
  • The findings published today further underscore the clinical utility of biomarker approaches to predict survival differences across BRCAwt and HRP positive ovarian cancer patients treated with Vigil.
  • Every year, an estimated 22,000 patients are diagnosed with ovarian cancer in the U.S. and 14,000 patients die.

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose

Retrieved on: 
Tuesday, July 12, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DED, Arizona State University, SEC, Nature, Associate, Pfizer, Family, Duane syndrome, Vaccine, Annual report, Severe acute respiratory syndrome coronavirus 2, Drug Quality and Security Act, Company, Securities Exchange Act of 1934, CEO, SAN, Medicine, Food, GLOBE, COVID-19, Diagnosis, Private Securities Litigation Reform Act, IP, Blood, Omicron, Trial of the century, Forward-looking statement, OU School of Community Medicine, Research, ASU, Securities Act of 1933, OTCQB, Pharmaceutical industry, Biotechnology

AXIM and ASU performed a clinical study using their co-developed rapid test and discovered that even after two doses, COVID-19 RNA vaccines were unable to elicit high levels of neutralizing antibodies in 25% of vaccine recipients.

Key Points: 
  • AXIM and ASU performed a clinical study using their co-developed rapid test and discovered that even after two doses, COVID-19 RNA vaccines were unable to elicit high levels of neutralizing antibodies in 25% of vaccine recipients.
  • However, a third vaccine dose rescued these vaccine poor responders, boosting their neutralizing antibodies to levels that are highly protective within two weeks of receiving a third dose.
  • The rapid 10-minute test quantitatively measures levels of neutralizing antibodies in a finger stick drop of blood.
  • This work underscores the importance of a third dose and that vaccine poor responders arent permanently poor responders they need another dose to be adequately protected.

Pandemic-related stressors in pregnant women may impact their babies before they’re born

Retrieved on: 
Thursday, May 26, 2022
Public policy, Harwell Science and Innovation Campus, Mood disorder, Hospital, Anxiety disorder, Development, Science, OU School of Community Medicine, Health, Pregnancy, Nursing, COVID-19, Bipolar disorder, Depression, Child, Life, U.S. News & World Report, Biochemistry, Fetus, Children's National Hospital, Anxiety, Human, Mental health, News, GLOBE, Medical imaging, D.C

This is what a study published in Communications Medicine suggests after following more than 200 pregnant women.

Key Points: 
  • This is what a study published in Communications Medicine suggests after following more than 200 pregnant women.
  • The psychosocial impact of COVID-19 on fetal brain development remains vastly understudied.
  • This study builds upon previous work from the Developing Brain Institute led by Limperopoulos, which discovered that anxiety in pregnant women appears to affect the brain development of their babies.
  • As a non-profit, Children's National Hospital relies on generous donors to help ensure that every child receives the care they need.

HJF Collaborates with Google Health and DoD to Use AI to Understand and Treat Breast Cancer Tumors

Retrieved on: 
Wednesday, August 11, 2021
Breast cancer, Factor X, Henry M. Jackson Foundation for the Advancement of Military Medicine, Histology, Military medicine, Artificial intelligence, HJF, Program, Cancer, Research, Deep learning, Multimedia, Neoplasm, OU School of Community Medicine, Biomarker, Naval Medical Center San Diego, Google Health, AI, HER2, Medical imaging

AI can predict three important biomarkers found in breast cancer.

Key Points: 
  • AI can predict three important biomarkers found in breast cancer.
  • Treatment plans forbreast cancer, one of the most common forms of cancer in the United States, rely on identification of biological molecules within the body, called biomarkers.
  • This research is the product of an ongoing collaboration between Google Health, NMCSD, and HJF.
  • This paper builds on research done in 2017 and 2018 where AI models were trained to identify metastatic breast cancer.

Ensemble Health Partners Announces Strategic Revenue Cycle Partnership with OU Medicine, Inc.

Retrieved on: 
Friday, February 19, 2021
OU Health, Oklahoma City, Geography of Oklahoma, University of Oklahoma, Health care, States of the United States, Oklahoma Children's Hospital, OU School of Community Medicine

Cincinnati, Ohio, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Ensemble Health Partners (Ensemble), a top-ranked leader in financial management services for health care providers, announced today that is has been selected by OU Medicine, Inc. as their strategic revenue cycle management partner.

Key Points: 
  • Cincinnati, Ohio, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Ensemble Health Partners (Ensemble), a top-ranked leader in financial management services for health care providers, announced today that is has been selected by OU Medicine, Inc. as their strategic revenue cycle management partner.
  • OU Medicine, Inc. is part of OU Health, which is the states only comprehensive academic health system of hospitals, clinics and centers of excellence, located in Oklahoma City and Tulsa, Oklahoma.
  • Ensemble offers full revenue cycle outsourcing as well as a comprehensive suite of healthcare financial management point solutions.
  • OU Health is the states only comprehensive academic health system of hospitals, clinics and centers of excellence.